Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
J Am Coll Cardiol. 2022; online ahead of print DOI: 10.1016/j.jacc.2022.07.021
Previous trials in HF with preserved LVEF have enrolled few patients who were recently hospitalised for HF. Furthermore, the EMPEROR-Preserved trial of empagliflozin excluded patients with acute decompensated HF within 1 week of screening or during the screening period before randomisation.
In DELIVER, around 10% of the study population had been recently hospitalised and were found to be at greater risk of the primary outcome of a worsening HF event or CV death than patients without recent hospitalisation. Dapagliflozin reduced the primary outcome similarly in patients with and without recent hospitalisation. Rates of adverse events, including volume depletion, diabetic ketoacidosis or renal events, were similar with dapagliflozin and placebo in recently hospitalised patients.